CULVER CITY, Calif. & NEWARK, N.J.--(BUSINESS WIRE)--NantHealth, Inc. (Nasdaq: NH):
WHAT: |
Panel discussion and press conference with Dr. Patrick Soon-Shiong, Founder and CEO of NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, and esteemed leadership of Horizon Blue Cross Blue Shield of New Jersey who will cover GPS Cancer tests to advance molecular science for its members enrolled in investigational studies for key cancer types—non-small cell lung cancer, breast cancer, colon cancer, and cancer of unknown primary—across leading health systems in the mid-Atlantic. These institutions, who will also participate in the panel discussion, include the Hospital of University of Pennsylvania (HUP), Cancer Institute of New Jersey, Hackensack Medical Center, Meridian Hospital and Regional Cancer Care Associates LLC (RCCA). They will also utilize COTA, Inc.’s analytics solution to monitor and track differences in clinical outcomes and cost-analysis throughout these investigational efforts. Representing COTA, Inc. on the panel will be Kelly Choi, MD, and Stuart Goldberg, MD.
|
||
-- Advancements in immunotherapy enabled by GPS Cancer to advance molecular science, which provide oncologists with unprecedented insights to help identify personalized, cost-effective therapy strategies before treatment begins. |
|||
-- How the studies can further the development and understanding of novel neoepitope antibodies, and their role in finally achieving low toxicity, targeted cancer therapy—with the ultimate hope of cancer antibodies or vaccines. |
|||
-- The role of machine learning in the complex understanding of the cancer genome and how NantWork’s Medical Reasoning Engine provides real-time predictive modeling and clinical outcomes that can continually improve physicians’ ability to make more effective care decisions. |
|||
-- How these initiatives can help address the new requirements of the Centers for Medicare and Medicaid Service (CMS) Oncology Care Model’s new targets for better care, smarter spending and healthier populations. |
|||
WHO: |
-- Dr. Patrick Soon-Shiong, Founder and CEO, NantWorks and leader of Cancer MoonShot2020 |
||
-- Allen Karp, SVP, Healthcare Management at Horizon Blue Cross Blue Shield New Jersey |
|||
-- Mary Ann Christopher, Chief of Clinical Operations and Transformation at Horizon Blue Cross Blue Shield New Jersey |
|||
-- Dr. Andrew Pecora, CIO, Hackensack University Medical Center |
|||
-- Dr. Shridar Ganesan, Rutgers Cancer Institute of New Jersey |
|||
-- Dr. Stuart Goldberg, COTA |
|||
-- Kyle Stern, Managing Partner, HealthScape Advisors |
|||
WHEN: |
Thursday, October 27, 2016, 2:00-3:00 p.m. ET | ||
WHERE: |
Horizon Blue Cross Blue Shield New Jersey |
||
3 Penn Plaza | |||
Newark, New Jersey | |||
Members of the media must RSVP to Kevin McArdle by noon, Oct. 26.
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients, as
well as our contribution to the Cancer 2020 initiative. Forward-looking
statements are subject to numerous risks and uncertainties that could
cause actual results to differ materially from currently anticipated
results. Factors that may cause future results to differ materially from
management’s current expectations include, among other things, that GPS
Cancer may not perform as anticipated, that sufficient physicians may
not adopt GPS Cancer to assist their diagnoses or that healthcare payers
may not provide reimbursement for GPS Cancer as expected. Our business
is subject to numerous additional risks and uncertainties, including,
among others, risks relating to market acceptance of our products; our
ability to successfully launch new products and applications;
competition; our sales, marketing and distribution capabilities; our
planned sales, marketing, and research and development activities;
unanticipated increases in costs or expenses; and risks associated with
international operations. Information on these and additional risks,
uncertainties, and other information affecting our business and
operating results can be found in our existing and future filings with
the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. We disclaim any obligation to update
these forward-looking statements except as may be required by law.
About NantHealth, Inc.
NantHealth, Inc., a member of
the NantWorks ecosystem of companies, is a next-generation,
evidence-based, personalized healthcare company enabling improved
patient outcomes and more effective treatment decisions for critical
illnesses. NantHealth‘s unique systems-based approach to personalized
healthcare applies novel diagnostics tailored to the specific molecular
profiles of patient tissues and integrates this molecular data in a
clinical setting with large-scale, real-time biometric signal and
phenotypic data to track patient outcomes and deliver precision
medicine. For nearly a decade, NantHealth has developed an adaptive
learning system, CLINICS, which includes its unique software, middleware
and hardware systems infrastructure that collects, indexes, analyzes and
interprets billions of molecular, clinical, operational and financial
data points derived from novel and traditional sources, continuously
improves decision-making and further optimizes our clinical pathways and
decision algorithms over time. For more information please visit www.nanthealth.com
and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular profile
analysis available through NantHealth. GPS Cancer integrates whole
genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and
quantitative proteomics through mass spectrometry, providing oncologists
with a comprehensive molecular profile of a patient’s cancer and an
assessment of protein pathway function to inform personalized treatment
strategies. GPS Cancer scanning is conducted in CLIA-certified and
CAP-accredited laboratories, and is a key enabler for Cancer MoonShot
2020, the world’s most comprehensive cancer collaborative initiative
seeking to accelerate the potential of combination immunotherapy as the
next generation standard of care in cancer patients. For more
information, visit www.gpscancer.com and
www.cancermoonshot2020.org.
About Horizon Blue Cross Blue Shield of New Jersey Horizon
Blue
Cross Blue Shield of New Jersey, the state's oldest and largest health
insurer is a tax-paying, not-for-profit health service corporation,
providing a wide array of medical, dental, and prescription insurance
products and services. Horizon BCBSNJ is leading the transformation of
health care in New Jersey by working with doctors and hospitals to
deliver innovative, patient-centered programs that reward the quality,
not quantity, of care patients receive. Learn more at www.HorizonBlue.com.
Horizon BCBSNJ is an independent licensee of the Blue Cross and Blue
Shield Association serving more than 3.8 million members.
About COTA, Inc.
COTA is the health care informatics and
precision analytics company that builds research-grade, real-world data
to exponentially improve outcomes, reduce cost and ensure the right care
for the right patient every time. The patented COTA Nodal Address System
(CNA) is the first and only digital classification system that
transforms prognostically significant variables into a digital code --
precisely categorizing patient factors, their diseases and intended
therapies to measure treatment outcomes, identify variances in care and
enable quality benchmarking, research, discovery and the transition to
value-based medicine. For more information, please visit www.oncota.com.
COTA - Best Care Made Clear.™